keyword
https://read.qxmd.com/read/38440701/ischemic-priapism-caused-by-self-intracavernous-injection-of-tadalafil
#21
Naoki Wada, Tsubasa Hatakeyama, Haruka Takagi, Ryoken Tsunekawa, Shin Kobayashi, Masaya Nagabuchi, Takeya Kitta, Hidehiro Kakizaki
INTRODUCTION: We present a case of ischemic priapism caused by self intracavernous injection of tadalafil. CASE PRESENTATION: A 77-year-old man developed priapism due to self-injection of tadalafil into the corpus cavernosum. He presented to our hospital 2 days after the development of priapism and severe penile pain. The blood gas analysis of the corpus cavernosum revealed ischemic priapism. At first, we performed percutaneous distal shunt (T-shunt) and cavernosal irrigation, resulting in slight improvement of penile tumescence...
March 2024: IJU case reports
https://read.qxmd.com/read/38435507/treatment-of-sexual-dysfunction-induced-by-hyperprolactinemia-accompanied-by-reduced-luteinizing-hormone-levels-a-case-report
#22
Tao Liu, Chao Jia, Yan Li
KEY CLINICAL MESSAGE: Sexual dysfunction induced by hyperprolactinemia accompanied by reduced luteinizing hormone (LH) is common in anrology clinics. A low dose of bromocriptine is helpful for restoring penile erectile function and libido in patients. ABSTRACT: Sexual dysfunction is closely related to hormonal disorders, of which prolactin (PRL) and luteinizing hormone (LH) disorders are common. How to treat sexual dysfunction induced by hyperprolactinemia accompanied by reduced LH levels is worth discussing...
March 2024: Clinical Case Reports
https://read.qxmd.com/read/38433177/evaluation-of-efficacy-and-safety-profile-of-tadalafil-5%C3%A2-mg-daily-dose-in-the-tablet-form-versus-oral-dispersible-film-in-men-with-mild-to-moderate-erectile-dysfunction-a-comparative-placebo-controlled-study
#23
JOURNAL ARTICLE
Ahmad T Motawi, Sameh Fayek GamalEl Din, Eslam M Meatmed, Ibrahim Fahmy
PURPOSE: We aimed to compare the efficacy, safety, and compliance of tadalafil 5 mg daily dose in the tablet form versus oral dispersible film (ODF) in men with mild-to-moderate erectile dysfunction (ED). METHODS: One hundred thirty-five randomized patients were equally divided into three groups according to age where each group included forty-five patients. Within each group, 15 patients received oral tadalafil 5 mg, 15 patients received ODF tadalafil 5 mg and 15 patients received a placebo once daily for 1 month...
March 4, 2024: International Urology and Nephrology
https://read.qxmd.com/read/38430634/a-multi-modal-approach-to-investigate-desmodium-gangeticum-s-influence-on-stress-induced-male-infertility-in-vivo-in-vitro-and-in-silico-assessments
#24
JOURNAL ARTICLE
Yahya S Alqahtani, Vijay R Chidrawar, Shruti Shiromwar, Sudarshan Singh, Rahul Maheshwari, Havagiray Chitme, Naresh Babu Chilamakuru, Popat Mohite, Ahmed M Aljameeli, Masood Medleri Khateeb
Physical and psychological stress has an inverse relation with male libido and sperm quality. The present study investigates the potential fertility-enhancing properties of Desmodium gangeticum (DG) root extracts in male Wister rats subjected to immobilization-induced stress (SIMB). DG roots were extracted using n-hexane (HEDG), chloroform (CEDG), and water (AEDG). In the pilot study, aphrodisiac protentional was investigated at two doses (125 and 250 mg kg-1 ) of each extract. In the main study, the HEDG and AEDG at 125 and 250 mg kg-1 were challenged for the stress by immobilization (SIMB), for 6 h daily over 28 days...
March 1, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38426421/treatment-preferences-of-patients-with-erectile-dysfunction-a-systematic-review-of-randomized-controlled-trials
#25
JOURNAL ARTICLE
Celeste Manfredi, Antonio Franco, Francesco Ditonno, Raman Mathur, Giorgio Franco, Riccardo Lombardo, Giorgio I Russo, Sabrina DE Cillis, Cristian Fiori, Davide Arcaniolo, Alessandro Antonelli, Riccardo Autorino, Marco DE Sio, Cosimo DE Nunzio
INTRODUCTION: Patients' treatment preferences (PTP) depend on the complex interaction of numerous patient- and treatment-related factors; their assessment can guide therapy and promote compliance of patients with erectile dysfunction (ED). We aimed to systematically describe the literature evaluating the treatment preferences of patients with ED, published in the last 25 years. EVIDENCE ACQUISITION: A comprehensive bibliographic search of multiple databases was conducted in June, 2023...
February 2024: Minerva urology and nephrology
https://read.qxmd.com/read/38413963/novel-drug-therapy-of-acute-hepatic-failure-induced-in-rats-by-a-combination-of-tadalafil-and-lepidium-sativum
#26
JOURNAL ARTICLE
Mahmoud S Sabra, Ahmed A Mohammed, Khaled M Ahmed Hassanein, Ahmed A N Ahmed, Dalia Hassan, Ebtsam S Abdel-Lah
BACKGROUND: Hepatocyte death and a systemic inflammatory response are the outcome of a complex chain of events mediated by numerous inflammatory cells and chemical mediators. The point of this study was to find out if tadalafil and/or Lepidium sativum (L. sativum) could help people who have been exposed to carbon tetrachloride (CCL4 ) and are experiencing acute moderate liver failure. This was especially true when the two were used together. METHOD AND MATERIALS: To cause mild liver failure 24 h before sacrifice, a single oral dosage of CCL4 (2...
February 27, 2024: BMC complementary medicine and therapies
https://read.qxmd.com/read/38379872/a-case-of-bullous-fixed-drug-eruption-caused-by-tadalafil
#27
Jane Sun Zhang, Ishita Aggarwal, Michelle Bain
No abstract text is available yet for this article.
March 2024: JAAD Case Reports
https://read.qxmd.com/read/38379558/case-report-extracorporeal-life-support-as-a-successful-bridge-to-recovery-in-an-incident-case-of-pulmonary-arterial-hypertension
#28
Benjamin Pequignot, Ari Chaouat, François Chabot, Bruno Levy, Simon Valentin
Pulmonary arterial hypertension (PAH) is characterized by a progressive increase in pulmonary vascular resistance (PVR) due to vascular remodeling of the small pulmonary arteries. In advanced RV failure or severe hypoxemia, extra corporeal life support (ECLS) is now to be considered, with the objective to bridge patients back to their baseline clinical state while waiting or right after lung transplantation, or bridge to pharmacological optimization of PAH (i.e., bridge to recovery). We describe herein a case of a 30-year-old woman ( gravida 6, para 6) with an incident case of heritable PAH revealed by refractory hypoxemia...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38378970/treatment-of-pulmonary-arterial-hypertension-in-patients-with-connective-tissue-diseases-a-systematic-review-and-meta-analysis
#29
JOURNAL ARTICLE
Mustafa Erdogan, Sinem Nihal Esatoglu, Burcak Kilickiran Avci, Gulen Hatemi
The evidence for the treatment of connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) mostly depends on subgroup or post hoc analysis of randomized controlled trials (RCTs). Thus, we performed a meta-analysis of RCTs that reported outcomes for CTD-PAH. PubMed and EMBASE were searched for CTD-PAH treatment. The selected outcomes were functional class (FC) change, survival rates, 6-min walk distance (6-MWD), clinical worsening (CW), N-terminal prohormone BNP (NT-proBNP), pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), right atrial pressure (RAP), and cardiac index (CI)...
February 20, 2024: Internal and Emergency Medicine
https://read.qxmd.com/read/38377158/evaluation-of-potential-urologic-prescription-drug-savings-with-mark-cuban-cost-plus-drug-company
#30
JOURNAL ARTICLE
Van Schloegel, Loyall Harris, Andrew Harris, Benjamin Dropkin
INTRODUCTION: Mark Cuban Cost Plus Drug Company (MCCPDC) launched in 2022 with a goal to decrease prescription drug costs. Thus far, research has focused on possible savings if Medicare purchased its annual volume of drugs at MCCPDC prices. The aim of this study is to analyze if MCCPDC can offer savings directly to urologic patients compared with other mail-order pharmacies, local pharmacies, and with patients using health insurance. METHODS: Twelve drugs used to treat urological diseases available on MCCPDC were analyzed...
March 2024: Urology Practice
https://read.qxmd.com/read/38377018/the-association-of-tadalafil-exposure-with-lower-rates-of-major-adverse-cardiovascular-events-and-mortality-in-a-general-population-of-men-with-erectile-dysfunction
#31
JOURNAL ARTICLE
Robert A Kloner, Eric Stanek, Karishma Desai, Christopher L Crowe, Kathryn Paige Ball, Aaron Haynes, Raymond C Rosen
BACKGROUND: Tadalafil is a long-acting phosphodiesterase-5 inhibitor (PDE-5i) indicated for erectile dysfunction (ED). HYPOTHESIS: Our hypothesis was that tadalafil will reduce the risk of major adverse cardiovascular events (MACE: composite of cardiovascular death, myocardial infarction, coronary revascularization, unstable angina, heart failure, stroke) and all-cause death in men with ED. METHODS: A retrospective observational cohort study was conducted in a large US commercial insurance claims database in men with a diagnosis of ED without prior MACE within 1 year...
February 2024: Clinical Cardiology
https://read.qxmd.com/read/38375500/analysis-of-vacuum-negative-pressure-therapy-and-traditional-chinese-medicine-lavage-in-combination-with-tadalafil-for-vascular-erectile-dysfunction
#32
REVIEW
Ke Liang, Zunjin Ke, Jianhong Huang, Xiang Fei, Liang Qi, Jie Wang
This study investigates the clinical effects of the novel Traditional Chinese Medicine (TCM) topical wash used in combination with negative pressure irrigation and tadalafil for the treatment of vascular erectile dysfunction. Eighty-seven patients with vascular erectile dysfunction were divided into an observation group and a control group. The observation group was administered negative pressure irrigation (TCM) in combination with oral tadalafil for four weeks, and the control group was administered oral tadalafil for four weeks...
2024: Front Reprod Health
https://read.qxmd.com/read/38339883/inhibition-of-pde-4-isoenzyme-attenuates-frequency-and-overall-contractility-of-agonist-evoked-ureteral-phasic-contractions
#33
JOURNAL ARTICLE
Iris Lim, Taishi Masutani, Hikaru Hashitani, Russ Chess-Williams, Donna Sellers
The aim of this study was to investigate the functional role of phosphodiesterase enzymes (PDE) in the isolated porcine ureter. Distal ureteral strips were mounted in organ baths and pre-contracted with 5-HT (100 μM). Upon generation of stable phasic contractions, PDE-4 and PDE-5 inhibitors were added cumulatively to separate tissues. PDE-4 inhibitors, such as rolipram (10 nM and greater) and roflumilast (100 nM and greater), resulted in significant attenuation of ureteral contractile responses, while a higher concentration of piclamilast (1 μM and greater) was required to induce a significant depressant effect...
February 2024: Pharmacology Research & Perspectives
https://read.qxmd.com/read/38331221/medications-mostly-associated-with-ejaculatory-disorders-assessment-of-the-eudravigilance-ev-and-food-and-drug-administration-fda-pharmacovigilance-databases-entries
#34
JOURNAL ARTICLE
Antonio Nacchia, Antonio Franco, Antonio Cicione, Sara Riolo, Giuseppe Santoro, Matteo Romagnoli, Luca Sarcinelli, Daniele Fiasconaro, Nicola Ghezzo, Giacomo Gallo, Giorgia Tema, Antonio Luigi Pastore, Yazan Al Salhi, Andrea Fuschi, Antonio Carbone, Giorgio Franco, Riccardo Lombardo, Andrea Tubaro, Cosimo De Nunzio
OBJECTIVES: To identify which medications are mostly associated with ejaculatory disorders through a disproportionality analysis. METHODS: The Food and Drug Administration Adverse Event Reporting System (FDA-FAERS) and the Eudra-Vigilance (EV) database were queried to identify medications more commonly associated to ejaculatory disorders from 10th September 2012 to 1st June 2023. Proportional Reported Ratios (PRRs) were computed for all the selected drugs. RESULTS: Overall, 7404 reports of ejaculatory disorders reports were identified, and of these, 6854 cases (92,6%) were attributed to ten specific medications...
February 6, 2024: Urology
https://read.qxmd.com/read/38308714/tadalafil-versus-tamsulosin-as-combination-therapy-with-5-alpha-reductase-inhibitors-in-benign-prostatic-hyperplasia-urinary-and-sexual-outcomes
#35
RANDOMIZED CONTROLLED TRIAL
Ahmed Tawfik, Mohammed Abo-Elenen, Mohammed Gaber, Ahmed El-Abd, Ahmed Zoeir, Sayed Saad, Intessar Sultan, Ayman Ghoneim
PURPOSE: To compare the urological and sexual outcomes of using either tamsulosin/finateride or tadalafil/finasteride as combination therapies in patients with large prostate. PATIENTS AND METHODS: Selection criteria included prostate volume > 40 ml and IPSS > 7. Patients with severe erectile dysfunction (IIEF-erectile functions ≤ 10) were excluded. Patients were randomized into group I (tamsulosin/finasteride) and group II (tadalafil/finasteride)...
February 3, 2024: World Journal of Urology
https://read.qxmd.com/read/38288222/pharmacological-approaches-in-managing-symptomatic-relief-of-benign-prostatic-hyperplasia-a-comprehensive-review
#36
REVIEW
Collyn O'Quin, Kathryn L White, John R Campbell, Sarah H Myers, Shilpadevi Patil, Debbie Chandler, Shahab Ahmadzadeh, Giustino Varrassi, Sahar Shekoohi, Alan D Kaye
Benign Prostatic Hyperplasia (BPH) is a prevalent condition that affects aging men, leading to the development of lower urinary tract symptoms (LUTS) and potentially severe complications such as complete obstruction. The management of BPH typically involves the use of medications from different classes, including alpha-1 antagonists, 5-alpha reductase inhibitors, and anticholinergics. Combination therapy utilizing drugs from different classes can also effectively manage the BPH-LUTS complex. Recent research has revealed that phosphodiesterase 5 (PDE5) inhibitors, including Tadalafil and Sildenafil, are highly effective in treating LUTS associated with BPH...
December 2023: Curēus
https://read.qxmd.com/read/38284776/long-term-tadalafil-once-daily-in-chinese-men-with-erectile-dysfunction-a-2-year-final-analysis-of-a-post-marketing-multicenter-randomized-open-label-trial
#37
JOURNAL ARTICLE
Hui Jiang, Lian-Ming Zhao, Su Yan, Ji-Hong Liu, Zhao-Hui Zhu, Jin-Dan Luo, Yu-Tian Dai, Fu-Biao Li, Hao-Cheng Lin, Zhi-Chao Zhang
The long-term safety and effectiveness of once-daily tadalafil is crucial, but limited data are available in Chinese patients with erectile dysfunction (ED). In this post-marketing, multicenter, randomized, open-label trial with 2-year follow-up, 635 ED cases were randomized to receive daily oral tadalafil 2.5 mg or 5 mg for 3 months, of whom 580 continued once-daily tadalafil 5 mg for 21 months. Treatment-emergent adverse events in the 12-month and 24-month period were similar, with the most common being viral upper respiratory tract infection, upper respiratory tract infection, and headache...
January 26, 2024: Asian Journal of Andrology
https://read.qxmd.com/read/38267109/double-down-on-single-tablet-combination-therapy-in-pulmonary-arterial-hypertension-possible-benefits-for-selected-patients
#38
EDITORIAL
Jeroen N Wessels, Harm Jan Bogaard
No abstract text is available yet for this article.
January 30, 2024: Journal of the American College of Cardiology
https://read.qxmd.com/read/38267108/randomized-trial-of-macitentan-tadalafil-single-tablet-combination-therapy-for-pulmonary-arterial-hypertension
#39
RANDOMIZED CONTROLLED TRIAL
Ekkehard Grünig, Pavel Jansa, Fenling Fan, Jakob A Hauser, Matthieu Pannaux, Adele Morganti, Hany Rofael, Kelly M Chin
BACKGROUND: Endothelin receptor antagonist (ERA) and phosphodiesterase 5 inhibitor (PDE5i) combination therapy is recommended for low-/intermediate-risk pulmonary arterial hypertension (PAH) patients. A fixed-dose combination of the ERA macitentan and PDE5i tadalafil (M/T FDC) in a once-daily, single tablet would simplify treatment. OBJECTIVES: The multicenter, double-blind, adaptive phase 3 A DUE study investigated the efficacy and safety of M/T FDC vs macitentan 10 mg and vs tadalafil 40 mg monotherapies in PAH patients, including treatment-naïve and prior ERA or PDE5i monotherapy-treated patients...
January 30, 2024: Journal of the American College of Cardiology
https://read.qxmd.com/read/38233015/risk-of-death-in-patients-with-coronary-artery-disease-taking-nitrates-and-phosphodiesterase-5-inhibitors
#40
JOURNAL ARTICLE
Ylva Trolle Lagerros, Alessandra Grotta, Sara Freyland, David Grannas, Daniel Peter Andersson
BACKGROUND: Phosphodiesterase-5 inhibitor (PDE5i) treatment for erectile dysfunction is associated with lower mortality compared with no treatment for erectile dysfunction after myocardial infarction (MI). There are conflicting results regarding the impact of PDE5i treatment on mortality in conjunction with nitrate medication. OBJECTIVES: The purpose of this study was to investigate the association between PDE5i treatment and cardiovascular outcomes in men with stable coronary artery disease treated with nitrate medication...
January 23, 2024: Journal of the American College of Cardiology
keyword
keyword
11515
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.